reptides › growth hormone › tesa+ipa blend

tesa+ipa blend

the GH-axis pairing built on the one GHRH leg that carries an FDA approval, tesamorelin, run alongside ipamorelin. the components are strong, the use is off-label, and the blend itself has no trial.

tier A · growth hormone · 1 of 2 FDA-approved GHRH leg

verdict

GHRH-plus-GHRP pharmacology where the GHRH half is the only one in its class with a full FDA approval. that approval covers HIV-associated visceral fat, not this blend and not this use.

if you're asking why pair tesamorelin instead of CJC-1295 or sermorelin — tesamorelin is the GHRH analog with the strongest human record. pooled phase 3 in HIV-associated lipodystrophy (n=806) showed 15-18% visceral-fat reduction at 26 weeks, CT-measured, and it carries a full FDA approval as Egrifta. that approval is narrow: HIV-associated visceral fat, not general recomp. ipamorelin supplies the ghrelin-receptor arm with the cleanest selectivity in its class. the pairing reaches for tesa's trial-grade GHRH leg plus ipa's clean GHRP leg.

if you're asking what the FDA approval actually covers here — tesamorelin alone is approved, for excess abdominal fat in HIV-associated lipodystrophy. the blend is not approved, and using tesamorelin for GH-axis recomp is off-label. ipamorelin has no approval and lost the 503A compounding pathway after the Oct 29, 2024 FDA PCAC vote. so one component carries real label data, the combined product carries none.

if you're asking what the synergy buys you — GHRH plus GHRP activates two separate pituitary receptors at once and produces a larger GH pulse than either arm alone. that synergy is textbook, demonstrated in humans for the receptor pair. what is missing is a fixed-blend outcome trial. the tesa+ipa product itself has no RCT. the evidence is component-derived plus clinic practice pattern.

based on published evidence and disclosed clinical practice. not medical advice.

why A-tier

A-tier reflects unusually strong component evidence: tesamorelin is the only GHRH analog with a full FDA approval and a phase 3 package, and ipamorelin has the cleanest GHRP selectivity data in its class. Not S, because that approval covers HIV-associated visceral fat rather than this blend or this GH-axis use, because using tesamorelin this way is off-label, and because no fixed-dose tesa+ipa outcome trial exists. The pharmacology is coherent and the components are well-documented; the combined product is still clinic practice rather than trial-grade evidence.

the core tension

One component carries a full FDA approval and a phase 3 package; the other carries the cleanest GHRP selectivity in its class. The receptor-pair pharmacology that joins them is established. What no part of the published record covers is the combined product: tesamorelin's approval is for HIV-associated visceral fat, not this blend, and no fixed-dose tesa+ipa outcome trial exists.

what it is

a GH-axis pairing: tesamorelin, a 44-amino-acid GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy, and ipamorelin, a selective ghrelin-receptor (GHS-R1a) pentapeptide. vial ratios and formulations vary by source. tesamorelin alone is FDA-approved for one narrow indication; the blend has no approved use, and both compounds sit on WADA's prohibited list.

what it does

hits both arms of GH release at once. tesamorelin supplies the GHRH-receptor signal that tells pituitary somatotrophs to fire; ipamorelin supplies the ghrelin-receptor signal on the same cells. together they amplify pulse amplitude more than either arm alone. the released GH drives liver IGF-1, the downstream signal behind body-composition and recovery effects.

origin

tesamorelin came from Theratechnologies, a small Montreal biotech, FDA-approved as Egrifta in 2010 and still approved only for HIV-associated lipodystrophy. ipamorelin came from Novo Nordisk in 1998 (code NNC 26-0161) and never reached commercial launch. the pairing is a newer extension of the GHRH-plus-GHRP logic that built the CJC+ipa stack: take the GHRH leg with the most human data and pair it with the cleanest GHRP.

why researchers are interested

the appeal is the GHRH half. tesamorelin is the only GHRH analog with a full FDA approval and a phase 3 package, so the pairing leans on trial-grade component data rather than mechanism alone on that side. ipamorelin adds a ghrelin-receptor arm that does not move cortisol, prolactin, or ACTH at clinically relevant doses. reports from users and clinics describe improved sleep depth, recovery, and modest body-composition shifts over weeks to months, alongside transient flushing, mild water retention, and occasional ghrelin-driven hunger. these are uncontrolled observations on an off-label use, not measured blend outcomes.

does it work

yes on receptor logic, with an honest asterisk on the product. the GHRH-plus-GHRP synergy is established in humans (Bowers 1990). tesamorelin's visceral-fat effect is phase 3 documented in HIV-associated lipodystrophy. ipamorelin's selectivity was nailed down by Raun in 1998. the missing piece is a fixed-blend outcome trial: nobody has run tesa+ipa as a combined product with endpoints. tesamorelin's approval does not cover this blend or this use, so the strongest data point on the page sits one step removed from what is actually in the vial.

claims vs the data

  • stacking GHRH and GHRP produces more GH than either alone — supported — established human pharmacology. GHRH hits the GHRH receptor on pituitary somatotrophs, ipamorelin hits the ghrelin receptor on the same cells. Bowers 1990 showed the two arms release GH synergistically in normal men. this is textbook receptor-pair logic.
  • the GHRH half is FDA-approved — partially true — tesamorelin alone is FDA-approved as Egrifta, but only for HIV-associated lipodystrophy. the blend has no approval, and using tesamorelin for general GH-axis recomp is off-label. component approval is not blend approval.
  • tesamorelin selectively reduces visceral fat — supported — pooled phase 3 (n=806) showed 15-18% visceral-fat reduction at 26 weeks, CT-measured, with subcutaneous fat unchanged. that record is HIV-derived; the population the trials studied is the bar.
  • the ipamorelin half is 'clean', no cortisol or prolactin spike — supported — Raun 1998 established ipamorelin's selectivity: no measurable change in cortisol, prolactin, FSH, LH, TSH, or ACTH at 200x the effective GH-release dose. that selectivity is why it's the preferred GHRP.
  • improves sleep, recovery, body composition as a blend — partially true — consistent user and clinic reports, and pharmacologically plausible through GH-axis signaling. direct controlled outcome trials of the tesa+ipa blend are missing.
  • the blend itself is FDA-approved for therapeutic use — contradicted — no fixed-dose tesa+ipa product is FDA-approved, and no blend RCT exists. tesamorelin's narrow HIV approval and research-vendor access do not equal approval of the combination.

key facts

  • molecular formula: C221H366N68O67S (tesamorelin) + C38H49N9O5 (ipamorelin)
  • molecular weight: 5135.8 + 711.85 Da
  • amino acids: 44 + 5
  • half-life: tesamorelin: ~26-38 min (subQ); ipamorelin: ~2 h
  • type: GHRH analog + GHRP blend
  • CAS: 901758-09-6 / 170851-70-4
  • 15-18% tesa VAT reduction (HIV phase 3)
  • 2010 tesamorelin FDA approval (egrifta)
  • 0 fixed-blend RCTs
  • 0x ipamorelin cortisol/prolactin rise

frequently asked questions

What is tesamorelin / ipamorelin blend?

A combination of two growth-hormone-axis peptides in a single vial: tesamorelin (a GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy) and ipamorelin (a selective ghrelin-receptor agonist). Together they hit both arms of GH release, the GHRH side and the GHRP side, for synergistic pulsatile GH stimulation.

What does tesamorelin / ipamorelin do?

Stimulates pulsatile growth hormone release through two complementary receptors. Tesamorelin (GHRH) tells pituitary somatotrophs to fire; ipamorelin (GHRP) amplifies the pulse via the ghrelin receptor. Sleep, recovery, and body-composition claims for the pairing are mostly clinic and community reports layered on component pharmacology, not direct blend trial outcomes.

How is tesamorelin / ipamorelin typically administered?

Research and clinic formulations vary, and there is no FDA-approved dosing framework for the blend. Tesamorelin alone has a labeled dose for HIV-associated lipodystrophy; the combined product does not. Community route and schedule claims are practice patterns, not label instructions.

What are the side effects of tesamorelin / ipamorelin?

Reported effects track the individual components: injection-site reactions, transient flushing, mild fluid retention, joint aches from GH/IGF-1 signaling, and occasional hunger from the ipamorelin half. Tesamorelin's label notes glucose-tolerance changes and roughly doubled IGF-1, both monitored in its trials.

Is tesamorelin / ipamorelin FDA approved?

The blend is not. Tesamorelin alone is FDA-approved as Egrifta for HIV-associated lipodystrophy, a narrow indication; using it in a GH-axis recomp blend is off-label. Ipamorelin has no FDA approval and lost the 503A compounding pathway after the October 2024 FDA PCAC vote. Both are on the WADA prohibited list.

How much does tesamorelin / ipamorelin cost?

Branded Egrifta carries orphan-drug pricing in its HIV indication. Research-vendor blend pricing is a small fraction of that and is not FDA-reviewed. Compounded access for the ipamorelin half narrowed after the FDA's 2024 503A action.

related peptides

  • tesamorelin — GHRH leg, the FDA-approved half
  • ipamorelin — GHRP leg, the clean selective half
  • cjc+ipa blend — the more common GHRH+GHRP stack
  • sermorelin — single-component GHRH alternative

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.